Natera Inc. Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while State Street Technology Select Sector SPDR ETF trades at $187.7 (market cap $129.38B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 2.3× Natera Inc. Common Stock's market cap, and State Street Technology Select Sector SPDR ETF is more actively traded (6,753,008 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| NTRA | XLK | |
|---|---|---|
Market Cap | $57.03B | $129.38B |
Volume | 1,131,157 | 6,753,008 |
Sector | Health | Sector/Thematic |
52-Week High | $425.64 | $202.00 |
52-Week Low | $179.42 | $127.49 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $56.18B | — |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XLK trades at $196.24, down slightly by 0.06% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF faces concentration concerns despite its tech sector exposure, with recent news highlighting AI-driven opportunities and potential interest rate impacts. Support levels are established at $195 and $194, with resistance at $198 and $199.
The outlook for XLK remains positive given strong AI investment themes and large-cap tech resilience, though risks include Fed rate hike sensitivity and sector concentration. Investor sentiment is mixed, balancing growth potential against macroeconomic headwinds and valuation pressures in the technology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →